Thank you to everyone who supported ALLG’s blood cancer research by donating to our 2025 tax appeal. Every donation matters and supports Better treatments…Better lives for people with blood cancer. Visit

Applications close on 18 July 2025 for the ALLG Anne Lenton Memorial Scholarship. Exclusively for ALLG Associate Members at regional, rural & remote hospital sites, with 2 prizes of $5,000 & $2,500 available. For more info or to apply, visit:

Donate today to our EOFY tax appeal to ensure all Australians can access lifesaving clinical research for blood cancer, no matter where they live. Donate here -

Today is Rare Cancer Awareness Day. Most blood cancer are rare & patients & clinicians facing unique challenges in treating them. ALLG’s clinical trials are is vital to making treatment breakthroughs that drive better treatments for rare blood cancers -

Congratulations to all ALLG members with abstract presentations at #EHA2025. The presence of our ALLG members highlights our leadership and contribution to global haematology research. More:

This tax time, support ALLG research & make a tax-deductible donation before 30 June. Or #doubleyourimpact in #workplacegivingmonth, with employer matching throughout June! Simply enrol your workplace, sign up to workplace giving & double your impact -

ALLG's BM12 CAST trial has shown game-changing results that will change 40 years of standard practice in GVHD prophylaxis. Presented at #EHA2025 by Professor David Curtis & published in NEJM. Read more about this breakthrough at

ALLG teletrials enable blood cancer patients all over Australia to access potentially life-saving blood cancer treatments via clinical trials. This tax time, donate to ALLG to ensure Better treatments…Better lives for Australians with blood cancer -

ALLG's BM12 CAST trial has shown game-changing results, changing 40 years of standard practice in GVHD prophylaxis for stem cell transplants. Presented at EHA2025 by Prof David Curtis & published in NEJM today, read more here: #clinicaltrials #EHA2025

Congratulations to all who were recognised in the King's Birthday Honours List 2025. We particularly congratulate those recognised for their efforts to advance health and medical research. To find out more, visit

Welcome to our ALLG 2025 Early Career Clinician Researchers - Dr Rakin Chowdury, Dr Sean McKeague & Dr Sonia Raj. This program provides mentorship & opportunities to pursue new clinical research in blood cancer -

Australians with blood cancer living in rural, regional and remote areas face more barriers to access clinical trials & cutting edge treatments. Donate to ALLG at this tax time to help us power equitable access to clinical trials for all Australians.

Mantle Cell Lymphoma (MCL) is in the news, with new treatments desperately needed for this rare & aggressive lymphoma. ALLG is leading the NHL37 GOLDiLox trial, investigating two new non-chemotherapy treatments to improve outcomes in relapsed MCL. More:

Today is #WorldBloodCancerDay. Nearly 20,000 Aussies are diagnosed with blood cancers like leukaemia, lymphoma & myeloma each year. At ALLG we drive life-changing clinical trial research to improve outcomes. Support our vital work at

ALLG's 2024 Research Report has launched, highlighting our clinical trial achievements, scientific insights & our impact for blood cancer patients across ANZ. We remain committed to our mission Better treatments. Better lives. Read more here:

To mark International Clinical Trials Day, the ALLG team came together to hear about our current trial progress and achievements. Patients are at the heart of ALLG's work as we pursue our mission of Better treatments. Better lives. For more, visit:

Today is International Clinical Trials Day & ALLG recognises our dedicated researchers, healthcare professionals & trial participants. The launch of ALLG's 2024 Research Report reinforces our ongoing commitment to improving patient outcomes. Read more at

International Clinical Trials Day is tomorrow. ALLG’s clinical trial portfolio is Powered By Purpose as it aims to treat rare types of cancer in underrepresented patient populations like our NHL32 study (PCNSL) which has reached recruitment.

That’s a wrap! ALLG’s Scientific Meeting was a terrific event. Thanks to all our members and industry partners for your engagement & support.

Today International Speaker Dr John F. DiPersio presented from Washington University School of Medicine on the use of Baricitinib for GVHD prophylaxis, in our Stem Cell Transplant Plenary. It was an insightful session focused on improving outcomes in transplant patients.